Research programme: T cell therapeutics - Celgene/Juno Therapeutics

Drug Profile

Research programme: T cell therapeutics - Celgene/Juno Therapeutics

Alternative Names: Autoimmune disorder therapeutics - Celgene/Juno; Cancer therapeutics - Celgene/Juno; CAR T cell products - Celgene/Juno; Chimeric antigen receptor T lymphocytes - Celgene/Juno; TCR T cell products - Celgene/Juno

Latest Information Update: 16 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celgene Corporation; Juno Therapeutics
  • Class CAR-T cell therapies; Immunotherapies
  • Mechanism of Action Immunomodulators; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Cancer

Most Recent Events

  • 29 Jun 2015 Celgene and Juno agree to co-develop and co-promote immunotherapies in countries worldwide for Cancer and Autoimmune disorders
  • 29 Jun 2015 Early research in Autoimmune disorders in USA (Parenteral)
  • 29 Jun 2015 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top